Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 3/2018

01-06-2018 | INTERSTITIAL LUNG DISEASE

Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias

Authors: Laurens J. De Sadeleer, Ellen De Langhe, Nicolas Bodart, Alain Vigneron, Xavier Bossuyt, Wim A. Wuyts

Published in: Lung | Issue 3/2018

Login to get access

Abstract

Although included in the serological domain of the ‘interstitial pneumonia with auto-immune features’ (IPAF) research statement, the search for myositis-specific antibodies (MSA) is not incorporated in routine clinical practice. The objective of the study was to evaluate MSA prevalence in an idiopathic interstitial pneumonia (IIP) cohort (n = 68) with suggestive morphological interstitial lung disease patterns. Twelve of 68 patients (17.6%) carried MSA, whereof only two were anti-nuclear antibody-positive. Besides female gender, no demographic or pulmonary function parameter was predictive for MSA positivity. MSA were present in 32.4% of IPAF patients (n = 37), being essential for IPAF diagnosis in four of them (10.8%).
Literature
1.
Kim H-C, Ji W, Kim MY, Colby TV, Jang SJ, Lee C-K, Han SB, Kim DS (2015) Interstitial pneumonia related to undifferentiated connective tissue disease. Chest 147:165–172CrossRefPubMed
2.
Fischer A, Antoniou KM, Brown KK et al (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987CrossRefPubMed
3.
Marie I, Hachulla E, Chérin P, Dominique S, Hatron P-Y, Hellot M-F, Devulder B, Herson S, Levesque H, Courtois H (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Care Res 47:614–622 (Hoboken)CrossRef
4.
5.
Lega J-C, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V (2015) Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 24:216–238CrossRefPubMed
6.
Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367–371CrossRefPubMedPubMedCentral
7.
Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, Ryu JH (2001) Polymyositis–dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–1185CrossRefPubMed
8.
Karadimitrakis S, Plastiras SC, Zormpala A, Chatzikonstantinou K, Boki KA, Tzelepis GE, Moutsopoulos HM (2008) Chest CT findings in patients with inflammatory myopathy and Jo1 antibodies. Eur J Radiol 66:27–30CrossRefPubMed
9.
Chua F, Higton AM, Colebatch AN, O’reilly K, Grubnic S, Vlahos I, Edwards CJ, Kiely PDW (2012) Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology 51:1870–1876 (United Kingdom)CrossRefPubMed
10.
Plastiras SC, Soliotis FC, Vlachoyiannopoulos P, Tzelepis GE (2007) Interstitial lung disease in a patient with antisynthetase syndrome and no myositis. Clin Rheumatol 26:108–111CrossRefPubMed
11.
Tzelepis GE, Toya SP, Moutsopoulos HM (2008) Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 31:11–20CrossRefPubMed
12.
Travis WD, Costabel U, Hansell DM et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748CrossRefPubMedPubMedCentral
13.
Garner R, Kumari R, Lanyon P, Doherty M, Zhang W (2015) Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 5:e006389CrossRefPubMedPubMedCentral
14.
Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, Kawano S, Kumagai S (2008) Prevalence of disease-specific antinuclear antibodies in general population: Estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol 18:153–160CrossRefPubMed
15.
Fish EN (2008) The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 8:737–744CrossRefPubMed
Metadata
Title
Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias
Authors
Laurens J. De Sadeleer
Ellen De Langhe
Nicolas Bodart
Alain Vigneron
Xavier Bossuyt
Wim A. Wuyts
Publication date
01-06-2018
Publisher
Springer US
Published in
Lung / Issue 3/2018
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-018-0108-8

Other articles of this Issue 3/2018

Lung 3/2018 Go to the issue

PULMONARY HYPERTENSION

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH

COPD

Can an Emergency Department Observation Unit Reduce Hospital Admissions for COPD Exacerbation?

BRIEF REPORT

Transdiaphragmatic Migration of a Spinal Fixation Rod into the Lung

ASTHMA

The Variants in the 3′ Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma

PULMONARY REHABILITATION

Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis

INTERSTITIAL LUNG DISEASE

Transient Blockade of Endothelin-1 Mitigates Amiodarone-Induced Pulmonary Fibrosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits